What's happening in the industry

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor read on...

GenomOncology and med fusion announce the addition of PD-L1 testing and interpretation to the LungSEQ® and 50SEQ® Plus FISH tests for NSCLC read on...

BMS expands focus on precision medicine with investment and planned research collaboration with GRAIL on blood-based cancer screening read on...

Invivoscribe announces long-term collaboration agreement with Illumina and plans release of NGS-based IVD assay kits read on...

Celgene and Agios gain FDA speedy review for AML med enasidenib read on...
PierianDx customers cite 'creative partnership' on clinical genomics as key selling point read on...

Computer trained to predict which AML patients will go into remission, which will relapse read on...

Philips and The Health Management Academy collaborate with top U.S. health systems to tackle key technology issues: population health, cybersecurity, big data read on...

NICE recommends wider use of tests to detect cancer-causing genetic condition read on...

This chip costs one cent and can diagnose everything from cancer to HIV read on...

Recent publication highlights proof-of-concept data supporting the diagnostic potential of phosphatidylserine-positive exosomes in ovarian cancer read on...

TG Therapeutics’ leukemia combo hits marks, guns for speedy FDA review read on...

IgG4-related disease biomarker development update presented at the 3rd International Symposium on IgG4-Related Diseases and Fibrosis read on...

Gene therapy for rheumatoid arthritis gets approval to start clinical trials read on...

Denovo Biopharma plans to launch a global Phase 3 trial of DB102 (Enzastaurin) in diffuse large B-cell lymphoma read on...

Assay identifies crizotinib-eligible lung cancer patients read on...

Top 15 pharma companies by 2016 revenue read on...

New BMS R&D Head read on...

Amgen submits supplemental biologics license application for BLINCYTO® (blinatumomab) in relapsed or refractory B-cell precursor acute lymphoblastic leukemia read on...

NanoString Technologies releases fourth quarter and full year 2016 operating results and provides 2017 outlook read on...

LabCorp to buy Pathology Associates Medical Laboratories read on...

Asuragen and Thermo Fisher Scientific to collaborate on diagnostic kits for 3500 Dx Series Genetic Analyzer read on...

Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization read on...

FDA announces preliminary list of 510(k) exempt devices read on...

Scott Gottlieb chosen for FDA read on...

UK rejects Merck's Keytruda as initial treatment for lung cancer read on...

What you might have missed

Media MentionDrug Industry Bets Big On Precision Medicine: Five Trends Shaping Care Delivery
Media MentionQ&A: Labceutics' Jordan Clark on Industry, FDA Gap on Rx/Dx Codevelopment Principles
Expert InsightWhite paper: Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product
PublicationThe Evolution of the PD-L1 Testing Market
PublicationImmuno-Oncology Drug Rivalries Highlight Biomarkers’ Opportunities, Challenges
Competitive Benchmarking ReportPharma Readiness for Diagnostic Integration 2017
Competitive Benchmarking ReportWhat are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany